Introduction
G-protein coupled receptor-119 (GPR119) agonism is known to modulate non-alcoholic fatty liver disease physiology. However, due to off-target effects, challenges remain for successful GPR119 agonist pharmacotherapy.
Designing a non-systemic drug candidate that locally targets gut-located receptors for incretin secretion is suggested as a safer approach to minimise conventional side effects. This strategy may potentially limit the direct action on pancreatic β-cells; however, chronic use may lead to beneficial outcomes.
We developed a novel small-molecule agent as an oleoyl-lysophosphatidylinositol derivative that stimulates intestinal glucagon-like peptide-1 (GLP-1) secretion by coupling with gut receptors at the orthosteric site.
Aims & Methods
The present study was designed to investigate the chronic impact of novel GPR119 agonist agent ps297 alone and in combination with Sitagliptin on liver health in high-fat diet (HFD)-induced obese mice.
Five-week-old healthy male C57BL6/J mice were fed with HFD for 20 weeks. Normal control mice were maintained on a standard chow diet. A dose-escalation protocol was followed during the treatment phase. Oral administration of the test compound commenced with an initial dose of 10 mg/kg/day for the first week, followed by weekly dose escalations of 10 mg/kg for the subsequent ten weeks until reaching a maximum dose concentration of 90 mg/kg/day. Sitagliptin was gavaged at a fixed dose of 20 mg/kg/day. Vehicle control mice received an equal volume of 0.25% carboxymethyl cellulose in water.
After ten weeks of treatment, blood samples were collected from each 4-hour fasted mice. Biochemical parameters including plasma glucose, triglycerides (TG), cholesterol (CHO), alanine aminotransferase (ALT), and aspartate transaminase (AST) were analysed using an automated analyser. Plasmatic concentrations of metabolic hormones were determined in a multiplex assay platform. Hepatic TG, CHO, and hydroxyproline concentrations were determined in frozen liver tissue samples by colourimetric assay. Liver histology was studied in tissue stored in 10% neutral buffered formalin. Hepatic ballooning was assessed in hematoxylin and eosin-stained sections, imaged using a slide scanner.
Results
Ten-week co-administration of compound ps297 with sitagliptin resulted in higher plasmatic GLP-1 levels compared to the HFD control arm, which led to a significant (p<0.05) reduction in fasting plasma glucose levels in this group. Moreover, combination group exhibited a significant reduction in liver weights (p<0.0001), plasma CHO (p<0.05), ALT (p<0.0001), and AST (p<0.01) levels. Furthermore, combination treatment showed a significant reduction in hepatic TG (p<0.0001) and CHO (p<0.001) concentrations compared to the HFD control group. Elevated hepatic hydroxyproline levels in HFD control mice were attenuated by combination treatment. Additionally, the hepatic ballooning score was found to be significantly reduced in the combination treatment mice.
Conclusion
Sitagliptin combination of ps297, improved glucose homeostasis in HFD-fed obese mice. Additionally, a prominent improvement in liver health status was observed in this group, as evident by reductions in liver weight, plasma liver enzymes, hepatic TG and CHO, and hydroxyproline levels. These findings were further supported by liver histological examination. The overall findings suggest the pharmacological potential of the GPR119 agonist compound ps297 in combination with gliptins to alleviate fatty liver disease, warranting further molecular investigation in disease-specific animal models.
References
Paternoster S, Simpson PV, Kokh E, Kizilkaya HS, Rosenkilde MM, Mancera RL, Keating DJ, Massi M, Falasca M. Pharmacological and structure-activity relationship studies of oleoyl-lysophosphatidylinositol synthetic mimetics. Pharmacol. Res. 172 (2021) 105822.
Bahirat UA, Shenoy RR, Talwar R, Goel RJ, Nemmani KVS. Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet. Biochem Biophys Res Commun 495 (2018) 1608-1613
Disclosure
MF and MM are inventors of a patent related to oleoyl-LPI mimetics. Curtin University received funding from Little Green Pharma Pty Ltd. to support MF to conduct the submitted work. LW is a paid employee of Little Green Pharma Pty Ltd. No other relationships or activities that could appear to have influenced the submitted work.